相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
B. Escudier et al.
ANNALS OF ONCOLOGY (2019)
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Brian I. Rini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Sunitinib for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis of Real-World and Clinical Trials Data
Michael Moran et al.
TARGETED ONCOLOGY (2019)
Changes in Treatment Reality and Survival of Patients With Advanced Clear Cell Renal Cell Carcinoma - Analyses From the German Clinical RCC-Registry
Peter J. Goebell et al.
CLINICAL GENITOURINARY CANCER (2018)
The use of real-world data in cancer drug development
E. Skovlund et al.
EUROPEAN JOURNAL OF CANCER (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Demographic Composition of Select Oncologic New Molecular Entities Approved by the FDA Between 2008 and 2017
Anuradha Ramamoorthy et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
Real world data: an opportunity to supplement existing evidence for the use of long-established medicines in health care decision making
Vaibhav B. Katkade et al.
JOURNAL OF MULTIDISCIPLINARY HEALTHCARE (2018)
Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial
Toni K. Choueiri et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapy
Kevin Zarrabi et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Real-world Data for Clinical Evidence Generation in Oncology
Sean Khozin et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Eligibility for phase 3 clinical trials of systemic therapy in real-world patients with metastatic renal cell cancer managed in a rural region
Carsten Nieder et al.
MEDICAL ONCOLOGY (2017)
Real-life patterns of use, safety and effectiveness of sunitinib in first-line therapy of metastatic renal cell carcinoma: the SANTORIN cohort study
Pernelle Noize et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2017)
Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatments
S. De Groot et al.
PLOS ONE (2017)
Real-world Data for Clinical Evidence Generation in Oncology
Sean Khozin et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Real-world costs and outcomes in metastatic renal cell carcinoma patients treated with targeted therapies: a cohort study from the French health insurance database
Rana Maroun et al.
CURRENT MEDICAL RESEARCH AND OPINION (2017)
Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors
Hai-Liang Zhang et al.
BMC CANCER (2017)
Treatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD registry
J. Wagstaff et al.
ANNALS OF ONCOLOGY (2016)
Validation of the International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) prognostic model for first-line pazopanib in metastatic renal carcinoma: the Spanish Oncologic Genitourinary Group (SOGUG) SPAZO study
B. Perez-Valderrama et al.
ANNALS OF ONCOLOGY (2016)
Outcomes of unselected patients with metastatic clear-cell renal cell carcinoma treated with first-line pazopanib therapy followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors or mammalian target of rapamycin inhibitors: a single institution experience
Marc R. Matrana et al.
BJU INTERNATIONAL (2016)
Survival among patients with advanced renal cell carcinoma in the pretargeted versus targeted therapy eras
Pengxiang Li et al.
CANCER MEDICINE (2016)
Variation in use of targeted therapies for metastatic renal cell carcinoma: Results from a Dutch population-based registry
S. De Groot et al.
BMC CANCER (2016)
Is real world evidence influencing practice? A systematic review of CPRD research in NICE guidances
Jessie O. Oyinlola et al.
BMC HEALTH SERVICES RESEARCH (2016)
Real-world data in the United Kingdom: opportunities and challenges
Laura McDonald et al.
BMC MEDICINE (2016)
Overall Survival Analysis From a Randomized Phase II Study of Axitinib With or Without Dose Titration in First-Line Metastatic Renal Cell Carcinoma
Brian I. Rini et al.
CLINICAL GENITOURINARY CANCER (2016)
Efficacy of Sunitinib in Elderly Patients with Metastatic Renal Cell Carcinoma: Data from Real-World Clinical Practice
Alexandr Poprach et al.
DRUGS & AGING (2016)
First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
Jose Manuel Ruiz-Morales et al.
EUROPEAN JOURNAL OF CANCER (2016)
The reporting of studies using routinely collected health data was often insufficient
Lars G. Hemkens et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2016)
IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial
Brian I. Rini et al.
LANCET ONCOLOGY (2016)
Everolimus versus sunitinib for patients with metastatic non-clear-cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial
Andrew J. Armstrong et al.
LANCET ONCOLOGY (2016)
Real-World Evidence - What Is It and What Can It Tell Us?
Rachel E. Sherman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Renal cell carcinoma recurrences and metastases in primary non-metastatic patients: a population-based study
Saeed Dabestani et al.
WORLD JOURNAL OF UROLOGY (2016)
Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis
Xinan Sheng et al.
ONCOTARGET (2016)
A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinoma
Moon Jin Kim et al.
BMC UROLOGY (2016)
Sequential Therapy in Metastatic Renal Cell Carcinoma
Bradford R. Hirsch et al.
JOURNAL OF KIDNEY CANCER AND VHL (2016)
Patient perceptions concerning clinical trials in oncology patients
A. L. Dias et al.
CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS (2016)
Patterns of care for metastatic renal cell carcinoma in Australia
Daphne Day et al.
BJU INTERNATIONAL (2015)
Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma
M. E. Gore et al.
BRITISH JOURNAL OF CANCER (2015)
Efficacy and Safety of an Attenuated-Dose Sunitinib Regimen in Metastatic Renal Cell Carcinoma: Results From a Prospective Registry in Singapore
Hui Shan Tan et al.
CLINICAL GENITOURINARY CANCER (2015)
First-Line and Sequential Use of Pazopanib Followed by Mammalian Target of Rapamycin Inhibitor Therapy Among Patients With Advanced Renal Cell Carcinoma in a US Community Oncology Setting
Nicholas J. Vogelzang et al.
CLINICAL GENITOURINARY CANCER (2015)
Efficacy and Safety of Sorafenib Therapy on Metastatic Renal Cell Carcinoma in Korean Patients: Results from a Retrospective Multicenter Study
Sung Han Kim et al.
PLOS ONE (2015)
Sunitinib dosing schedule 2/1 improves tolerability, efficacy, and health-related quality of life in Chinese patients with metastatic renal cell carcinoma
Xiuwu Pan et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2015)
Clinicopathological and prognostic factors for long-term survival in Chinese patients with metastatic renal cell carcinoma treated with sorafenib: a single-center retrospective study
Hai-Liang Zhang et al.
ONCOTARGET (2015)
The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement
Eric I. Benchimol et al.
PLOS MEDICINE (2015)
Sunitinib in metastatic renal cell carcinoma: a systematic review of UK real world data
Miriam Argyropulo-Palmer et al.
FRONTIERS IN ONCOLOGY (2015)
Clinical Trial Participants With Metastatic Renal Cell Carcinoma Differ From Patients Treated in Real-World Practice
Aaron P. Mitchell et al.
JOURNAL OF ONCOLOGY PRACTICE (2015)
Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials
D. Y. C. Heng et al.
ANNALS OF ONCOLOGY (2014)
Standard vs Adapted Sunitinib Regimen in Elderly Patients With Metastatic Renal Cell Cancer: Results From a Large Retrospective Analysis
Ugo De Giorgi et al.
CLINICAL GENITOURINARY CANCER (2014)
Dosing Patterns, Toxicity, and Outcomes in Patients Treated With First-Line Sunitinib for Advanced Renal Cell Carcinoma in Community-Based Practices
Ian D. Schnadig et al.
CLINICAL GENITOURINARY CANCER (2014)
Phase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With Metastatic Renal Cell Carcinoma
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Assessment of efficacy, safety and quality of life of 110 patients treated with sunitinib as first-line therapy for metastatic renal cell carcinoma: experience in real-world clinical practice in Japan
Hideaki Miyake et al.
MEDICAL ONCOLOGY (2014)
Real-World Outcomes in Metastatic Renal Cell Carcinoma: Insights From a Joint Community-Academic Registry
Michael R. Harrison et al.
JOURNAL OF ONCOLOGY PRACTICE (2014)
Overall survival for sorafenib plus interleukin-2 compared with sorafenib alone in metastatic renal cell carcinoma (mRCC): final results of the ROSORC trial
G. Procopio et al.
ANNALS OF ONCOLOGY (2013)
Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial
Thomas E. Hutson et al.
LANCET ONCOLOGY (2013)
Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
THE EFFECT OF ENGLISH-LANGUAGE RESTRICTION ON SYSTEMATIC REVIEW-BASED META-ANALYSES: A SYSTEMATIC REVIEW OF EMPIRICAL STUDIES
Andra Morrison et al.
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2012)
Randomized Phase II Trial of Sunitinib on an Intermittent Versus Continuous Dosing Schedule As First-Line Therapy for Advanced Renal Cell Carcinoma
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial
G. Procopio et al.
BRITISH JOURNAL OF CANCER (2011)
Prognostic stratification of patients with advanced renal cell carcinoma treated with sunitinib: comparison with the Memorial Sloan-Kettering prognostic factors model
Aristotelis Bamias et al.
BMC CANCER (2010)
Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials
Anneke T. Schroen et al.
CLINICAL TRIALS (2010)
Commentary: External validity of results of randomized trials: disentangling a complex concept
Peter M. Rothwell
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2010)
How to assess the external validity of therapeutic trials: a conceptual approach
O. M. Dekkers et al.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2010)
A Population based Study Evaluating the Impact of Sunitinb on Overall Survival in the Treatment of Patients With Metastatic Renal Cell Cancer
Daniel Y. C. Heng et al.
CANCER (2009)
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration
Alessandro Liberati et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2009)
Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma
Bernard Escudier et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Young Age Is Independent Prognostic Factor for Cancer-Specific Survival of Low-Stage Clear Cell Renal Cell Carcinoma
Eun-Jung Jung et al.
UROLOGY (2009)
Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma:: A randomized phase III clinical trial
Alain Ravaud et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Racial/ethnic and gender disparities in renal cell carcinoma incidence and survival
Helen Shi Stafford et al.
JOURNAL OF UROLOGY (2008)
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies
Erik von Elm et al.
LANCET (2007)
Eligibility criteria of randomized controlled trials published in high-impact general medical journals - A systematic sampling review
Harriette G. C. Van Spall et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Treating Individuals 1 - External validity of randomised controlled trials: To whom do the results of this trial apply?'
PM Rothwell
LANCET (2005)
Participation in cancer clinical trials - Race-, sex-, and age-based disparities
VH Murthy et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
分享论文
